Atlanta, GA (PRWEB) March 28, 2012
Aderans Research reached a major milestone this month with the completion of enrollment in one of its key Phase 2 clinical protocols. A total of more than 350 subjects across the country are enrolled in the trial, which evaluates the effect of Aderans’ unique Ji Gami™ family of cell products on pattern hair loss.
“We’re thrilled to reach this landmark in our research,” said Vern Liebmann, Aderans Research Chief Operating Officer. “We are looking forward to sharing the advances we’ve made in the field of hair regeneration.”
Aderans expects to tabulate, analyze and present their findings at the conclusion of the trial. In the meantime, more clinical protocols are in the works to test additional products coming down the pipeline and see how they might benefit patients with male and female pattern hair loss.
“Our cell engineering solutions offer a completely new approach to treatment for the millions of people who suffer from hair loss,” said Aderans Research Chief Executive Officer Ken Washenik, M.D., Ph.D. “The results to date are promising, and with the enrollment complete in this Phase 2 protocol, we’re getting even closer to a solution.”
A pioneer in its field, Aderans Research is committed to developing innovative solutions for those who struggle with hair loss. For more information about Aderans Research, visit http://www.aderansresearch.com.
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. Located in Atlanta, Aderans Research is a subsidiary of Aderans Co., Ltd, the world’s largest wig manufacturer, and affiliate of Bosley, a global leader in surgical hair restoration.
Ongoing information on ARI’s clinical study can be seen at http://aderansresearch.com/ari_clinicalupdates.html.
Additional information on ARI can be found at http://www.aderansresearch.com.